At a glance
- Originator Ajinomoto
- Class Antifungals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 01 Oct 2004 Discontinued - Preclinical for Mycoses in Japan (unspecified route)
- 13 Nov 2001 No-Development-Reported for Mycoses in Japan (Unknown route)
- 02 Feb 1998 Preclinical development for Mycoses in Japan (Unknown route)